Gender bias in cardiovascular advertisements
Sofia B Ahmed1, Sherry L Grace, Henry Thomas Stelfox
1Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Insights
Cardiovascular advertisements overwhelmingly feature male patients, not female patients. This gender bias in medical advertising may contribute to disparities in women's cardiovascular disease treatment.
Area of Science:
- Medical Marketing and Communications
- Cardiovascular Disease Epidemiology
- Health Disparities Research
Background:
- Women with cardiovascular disease (CVD) often receive less aggressive treatment compared to men, a disparity with unclear origins.
- Pharmaceutical advertisements in medical journals may influence physician prescribing habits and patient care decisions.
- Understanding representation in medical advertising is crucial for addressing potential biases in healthcare.
Purpose of the Study:
- To investigate gender representation in pharmaceutical advertisements related to cardiovascular disease.
- To determine if female and male patients are depicted equally in cardiovascular advertisements within medical journals.
Main Methods:
- Analysis of all cardiovascular advertisements from US general medical and cardiovascular journals between January 1996 and June 1998.
- Data collection included advertisement frequency, placement in premium journal positions, and demographic characteristics (gender, age, race, role) of featured individuals.
- Advertisements were categorized based on the primary figure and the predominant gender depicted.
Main Results:
- Out of 919 unique advertisements, 254 featured a patient. Of these, 20% depicted female patients versus 80% depicting male patients (P <0.0001).
- Advertisements featuring female patients appeared significantly less often (13.3%) than those featuring male patients (86.7%) (P <0.0001).
- Female patient advertisements also had fewer mean appearances in premium journal positions compared to male patient advertisements (0.82 vs. 1.99, P=0.02).
Conclusions:
- Significant under-representation of female patients in cardiovascular advertisements persists, despite increased focus on women's CVD.
- This gender bias in advertising may perpetuate disparities in the diagnosis and treatment of cardiovascular disease in women.
- Healthcare providers should be aware of this advertising bias to ensure equitable patient care.
Rationale:
Women with cardiovascular disease are treated less aggressively than men. The reasons for this disparity are unclear. Pharmaceutical advertisements may influence physician practices and patient care.
Aims And Objective:
To determine if female and male patients are equally likely to be featured in cardiovascular advertisements.
Methods:
We examined all cardiovascular advertisements from US editions of general medical and cardiovascular journals published between 1 January 1996 and 30 June 1998. For each unique advertisement, we recorded the total number of journal appearances and the number of appearances in journals' premium positions. We noted the gender, age, race and role of both the primary figure and the majority of people featured in the advertisement.
Results:
Nine hundred and nineteen unique cardiovascular advertisements were identified of which 254 depicted a patient as the primary figure. A total of 20%[95% confidence interval (CI) 15.3-25.5%] of these advertisements portrayed a female patient, while 80% (95% CI 74.5-84.7%) depicted a male patient, P <0.0001. Female patient advertisements appeared 249 times (13.3%; 95% CI 8.6-18.9%) while male patient advertisements appeared 1618 times (86.7%; 95% CI 81.1-91.4%), P <0.0001. Female patient advertisements also had significantly fewer mean appearances than male patient advertisements in journals' premium positions (0.82 vs. 1.99, P=0.02). Similar results were seen when the advertisements were analysed according to predominant gender.
Conclusions:
Despite increasing emphasis on cardiovascular disease in women, significant under-representation of female patients exists in cardiovascular advertisements. Physicians should be cognizant of this gender bias.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:27Regulation of the Cardiovascular System
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...
01:23Assessment of the Cardiovascular System I: Subjective Data
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers